Post –Stabilisation Period Announcement

·2 min read

LONDON, December 01, 2021--(BUSINESS WIRE)--

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.


Post –Stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 02/11/2021, Natixis S.A. (contact: Jean Dado; telephone: +44 20 32 16 95 60 / contact: Terence Sands; telephone: +44 20 32 16 92 40) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager named below in relation to the offer of the following securities.





On the Issue Date, the Notes will be senior obligations of the Issuer and guaranteed on a senior basis by Laboratoire Eimer, Bio Lam LCD, Biomer, BPO-Bioépine, LBM Bioesterel, Astralab, Laborizon Maine Anjou, Laborizon Bretagne, Laborizon Centre, Unilians Biogroup, Biosynergie, Medisch Labo Medina BV, Macsys NV and Centrum voor Medische Analyse BV

Aggregate nominal amount



3.375% Notes due 2028

Offer price:


Stabilisation Manager


Natixis S.A.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within Article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

View source version on


Natixis Syndicate

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting